

Roberto Latini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4181274/publications.pdf>

Version: 2024-02-01

377
papers

29,705
citations

6592

79
h-index

5519

163
g-index

388
all docs

388
docs citations

388
times ranked

25174
citing authors

#	ARTICLE	IF	CITATIONS
1	A Trial of Goal-Oriented Hemodynamic Therapy in Critically Ill Patients. <i>New England Journal of Medicine</i> , 1995, 333, 1025-1032.	13.9	1,502
2	Effect of Prone Positioning on the Survival of Patients with Acute Respiratory Failure. <i>New England Journal of Medicine</i> , 2001, 345, 568-573.	13.9	1,184
3	Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 1223-1230.	6.3	1,178
4	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 1231-1239.	6.3	954
5	Albumin Replacement in Patients with Severe Sepsis or Septic Shock. <i>New England Journal of Medicine</i> , 2014, 370, 1412-1421.	13.9	947
6	Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure. <i>Circulation</i> , 1999, 100, 1056-1064.	1.6	842
7	Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT). <i>Circulation</i> , 2003, 107, 1278-1283.	1.6	786
8	Erythropoietin mediates tissue protection through an erythropoietin and common \hat{A} -subunit heteroreceptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14907-14912.	3.3	657
9	Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1242-1249.	1.6	635
10	Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 4802-4806.	3.3	556
11	Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2010, 36, 585-599.	3.9	486
12	Prone Positioning in Patients With Moderate and Severe Acute Respiratory Distress Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1977.	3.8	459
13	Valsartan for Prevention of Recurrent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 360, 1606-1617.	13.9	442
14	Disruption of the Ang II type 1 receptor promotes longevity in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 524-530.	3.9	434
15	Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction. <i>Circulation</i> , 2004, 110, 2349-2354.	1.6	402
16	Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). <i>American Heart Journal</i> , 2005, 149, 548-557.	1.2	401
17	C-Reactive Protein in Heart Failure. <i>Circulation</i> , 2005, 112, 1428-1434.	1.6	393
18	PTX3, A Prototypical Long Pentraxin, Is an Early Indicator of Acute Myocardial Infarction in Humans. <i>Circulation</i> , 2000, 102, 636-641.	1.6	384

#	ARTICLE	IF	CITATIONS
19	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017, 377, 41-51.	13.9	355
20	Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. <i>Circulation: Heart Failure</i> , 2008, 1, 17-24.	1.6	340
21	Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1414-1421.	1.2	331
22	Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction. <i>Circulation</i> , 2008, 117, 1055-1064.	1.6	322
23	The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. <i>European Heart Journal</i> , 2004, 25, 292-299.	1.0	319
24	Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data. <i>Clinical Chemistry</i> , 2006, 52, 1528-1538.	1.5	317
25	Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart) Tj ETQq1 1 0.784314 rgBT /Ove	1.2	301
26	Myocyte Death in Streptozotocin-Induced Diabetes in Rats Is Angiotensin II- Dependent. <i>Laboratory Investigation</i> , 2000, 80, 513-527.	1.7	287
27	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 119-129.	2.9	281
28	Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 2454-2458.	1.6	279
29	Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure. <i>Circulation</i> , 2005, 112, 1121-1127.	1.6	243
30	Influence of diabetes on mortality in acute myocardial infarction: Data from the GISSI-2 study. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1788-1794.	1.2	242
31	A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2046-2051.	3.3	231
32	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. <i>Lancet</i> , The, 2002, 360, 1037-1043.	6.3	230
33	Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. <i>Journal of the American College of Cardiology</i> , 2002, 40, 970-975.	1.2	228
34	Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. <i>European Heart Journal</i> , 2000, 21, 1368-1375.	1.0	224
35	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 635-641.	2.9	214
36	Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure. <i>Circulation</i> , 2012, 125, 280-288.	1.6	209

#	ARTICLE	IF	CITATIONS
37	Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2022-2027.	1.2	206
38	Prognostic Significance of Heart Rate Variability in Post-Myocardial Infarction Patients in the Fibrinolytic Era. <i>Circulation</i> , 1996, 94, 432-436.	1.6	204
39	Fish Oil and Postoperative Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2001.	3.8	201
40	Effect of prone positioning during mechanical ventilation on mortality among patients with acute respiratory distress syndrome: a systematic review and meta-analysis. <i>Cmaj</i> , 2014, 186, E381-E390.	0.9	200
41	ACE Inhibitor Use in Patients With Myocardial Infarction. <i>Circulation</i> , 1995, 92, 3132-3137.	1.6	190
42	Effect of the ACE Inhibitor Lisinopril on Mortality in Diabetic Patients With Acute Myocardial Infarction. <i>Circulation</i> , 1997, 96, 4239-4245.	1.6	188
43	Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 959-968.	0.9	182
44	Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. <i>Critical Care</i> , 2014, 18, R6.	2.5	175
45	Clinical outcome of renal tubular damage in chronic heart failure. <i>European Heart Journal</i> , 2011, 32, 2705-2712.	1.0	174
46	Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. <i>Journal of Clinical Investigation</i> , 2009, 119, 3356-72.	3.9	167
47	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-oneAtrial. <i>European Journal of Cancer</i> , 2018, 94, 126-137.	1.3	163
48	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
49	Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1801-1807.	1.2	156
50	Cyclosporine A in Reperfused Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 365-374.	1.2	144
51	Doppler-derived mitral deceleration time as a strong prognostic marker of left ventricular remodeling and survival after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1646-1653.	1.2	137
52	Cytokines in Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 1.	0.8	129
53	The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 338-347.	2.9	129
54	Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach. <i>Scientific Reports</i> , 2016, 6, 20391.	1.6	126

#	ARTICLE	IF	CITATIONS
55	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	1.2	126
56	Anemia in Patients With Heart Failure: Prevalence and Prognostic Role in a Controlled Trial and in Clinical Practice. <i>Journal of Cardiac Failure</i> , 2005, 11, 91-98.	0.7	118
57	Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. <i>Intensive Care Medicine</i> , 2015, 41, 12-20.	3.9	114
58	Junctional adhesion molecule-A-deficient polymorphonuclear cells show reduced diapedesis in peritonitis and heart ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10634-10639.	3.3	113
59	The long pentraxin PTX3 in vascular pathology. <i>Vascular Pharmacology</i> , 2006, 45, 326-330.	1.0	109
60	Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. <i>Circulation</i> , 1985, 72, 1185-1193.	1.6	107
61	The prognostic value of pre-discharge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. <i>European Heart Journal</i> , 1996, 17, 1646-1656.	1.0	104
62	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. <i>European Journal of Heart Failure</i> , 2015, 17, 424-433.	2.9	104
63	Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 65-72.	1.6	101
64	Pentraxin 3 in Cardiovascular Disease. <i>Frontiers in Immunology</i> , 2019, 10, 823.	2.2	100
65	Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-HF study): final results. <i>European Journal of Heart Failure</i> , 2009, 11, 68-76.	2.9	99
66	Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. <i>European Heart Journal</i> , 2009, 30, 2327-2336.	1.0	98
67	Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. <i>Life Sciences</i> , 2006, 79, 121-129.	2.0	96
68	Incremental Prognostic Value of Changes in B-Type Natriuretic Peptide in Heart Failure. <i>American Journal of Medicine</i> , 2006, 119, 70.e23-70.e30.	0.6	95
69	Effects of Exercise Training on Endothelial Progenitor Cells in Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 701-708.	0.7	95
70	Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. <i>Cell Death and Differentiation</i> , 2008, 15, 1417-1428.	5.0	94
71	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	2.9	93
72	Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. <i>European Journal of Heart Failure</i> , 2012, 14, 718-729.	2.9	92

#	ARTICLE	IF	CITATIONS
73	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 1486-1494.	1.6	92
74	Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure. <i>Circulation</i> , 2003, 108, 1306-1309.	1.6	91
75	Pentraxin α 3 in chronic heart failure: the CORONA and GISSI α HF trials. <i>European Journal of Heart Failure</i> , 2012, 14, 992-999.	2.9	91
76	Understanding Lactatemia in Human Sepsis. Potential Impact for Early Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 582-589.	2.5	90
77	Mesoangioblasts, Vessel-Associated Multipotent Stem Cells, Repair the Infarcted Heart by Multiple Cellular Mechanisms. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 692-697.	1.1	88
78	Tubular Damage and Worsening Renal Function in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 417-424.	1.9	87
79	Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. <i>Intensive Care Medicine Experimental</i> , 2015, 3, 44.	0.9	81
80	Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2007, 13, 797-804.	0.7	80
81	Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. <i>Medicina (Lithuania)</i> , 2019, 55, 525.	0.8	80
82	Kitcre knock-in mice fail to fate-map cardiac stem cells. <i>Nature</i> , 2018, 555, E1-E5.	18.7	79
83	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart α OMics α ™ in AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , 2021, 42, 684-696.	1.0	77
84	Amplitude Spectrum Area to Guide Defibrillation. <i>Circulation</i> , 2015, 131, 478-487.	1.6	76
85	Effects of ω -3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI α HF trial. <i>European Journal of Heart Failure</i> , 2010, 12, 1345-1353.	2.9	75
86	Sequential N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin Measurements During Albumin Replacement in Patients With Severe Sepsis or Septic Shock*. <i>Critical Care Medicine</i> , 2016, 44, 707-716.	0.4	75
87	Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial. <i>European Journal of Heart Failure</i> , 2007, 9, 397-402.	2.9	72
88	Comparison of Brain Natriuretic Peptide Plasma Levels Versus Logistic EuroSCORE in Predicting In-Hospital and Late Postoperative Mortality in Patients Undergoing Aortic Valve Replacement for Symptomatic Aortic Stenosis. <i>American Journal of Cardiology</i> , 2008, 102, 749-754.	0.7	71
89	Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial. <i>European Journal of Clinical Investigation</i> , 2017, 47, 73-83.	1.7	71
90	Appraisal of the Role of Angiotensin II and Aldosterone in Ventricular Myocyte Apoptosis in Adult Normotensive Rat. <i>Journal of Molecular and Cellular Cardiology</i> , 2002, 34, 1655-1665.	0.9	70

#	ARTICLE	IF	CITATIONS
91	A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia during elective craniotomy. <i>European Journal of Anaesthesiology</i> , 2012, 29, 371-379.	0.7	69
92	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 376, 890-892.	13.9	69
93	Ventricular arrhythmias and four-year mortality in haemodialysis patients. <i>Lancet, The</i> , 1992, 339, 212-213.	6.3	68
94	Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 761-3.	1.4	68
95	Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both. <i>American Journal of Cardiology</i> , 2005, 96, 698-704.	0.7	67
96	Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT. <i>International Journal of Cardiology</i> , 2007, 119, 48-53.	0.8	66
97	Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis. <i>Critical Care Medicine</i> , 2018, 46, e221-e228.	0.4	65
98	Up-Regulation of AT1 and AT2 Receptors in Postinfarcted Hypertrophied Myocytes and Stretch-Mediated Apoptotic Cell Death. <i>American Journal of Pathology</i> , 2000, 156, 1663-1672.	1.9	64
99	Semaphorin 4A Exerts a Proangiogenic Effect by Enhancing Vascular Endothelial Growth Factor-A Expression in Macrophages. <i>Journal of Immunology</i> , 2012, 188, 4081-4092.	0.4	64
100	Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1704-1717.	2.3	64
101	Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial. <i>Journal of Internal Medicine</i> , 2011, 269, 160-171.	2.7	63
102	Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 78-85.	2.9	63
103	Predicting the effects of supplemental EPA and DHA on the omega-3 index. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 1034-1040.	2.2	63
104	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005897.	1.6	63
105	Lung Injury and Recovery in a Murine Model of Unilateral Acid Aspiration. <i>Anesthesiology</i> , 2008, 108, 1037-1046.	1.3	63
106	Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , 2010, 16, 964-970.	0.7	62
107	The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , 2006, 12, 375-380.	0.7	61
108	Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. <i>American Heart Journal</i> , 2010, 160, 286-293.	1.2	60

#	ARTICLE	IF	CITATIONS
109	Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: Relation with fish intake, circulating biomarkers, and mortality. <i>American Heart Journal</i> , 2013, 165, 208-215.e4.	1.2	60
110	Age-dependent expression of fibrosis-related genes and collagen deposition in the rat myocardium. This study was presented in part at the 49th Annual Meeting of the 'Gerontological Society of America', Washington, November 17-21, 1996. <i>Mechanisms of Ageing and Development</i> , 1998, 101, 57-72.	2.2	59
111	Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis. <i>Chest</i> , 2017, 152, 312-320.	0.4	59
112	Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition. <i>Journal of Clinical Investigation</i> , 1981, 68, 1108-1112.	3.9	57
113	Remodelling of Cardiac Extracellular Matrix during β -adrenergic Stimulation: Upregulation of SPARC in the Myocardium of Adult Rats. <i>Journal of Molecular and Cellular Cardiology</i> , 1998, 30, 1505-1514.	0.9	55
114	Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. <i>American Heart Journal</i> , 2011, 161, 338-343.e1.	1.2	53
115	Fish Oil and Post-Operative Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2194-2196.	1.2	52
116	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	2.9	52
117	Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. <i>European Journal of Heart Failure</i> , 2013, 15, 1236-1244.	2.9	51
118	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella) <i>TJ ETQq0 O1OrgBT /Overlock 10</i>		
119	A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2007, 9, 129-135.	2.9	50
120	Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. <i>European Journal of Heart Failure</i> , 2010, 12, 549-556.	2.9	50
121	Postresuscitation Treatment With Argon Improves Early Neurological Recovery in a Porcine Model of Cardiac Arrest. <i>Shock</i> , 2014, 41, 72-78.	1.0	49
122	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart OMICS in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , 2016, 14, 181.	2.3	48
123	Murine models of myocardial and limb ischemia: Diagnostic end-points and relevance to clinical problems. <i>Vascular Pharmacology</i> , 2006, 45, 281-301.	1.0	47
124	Pentraxins and Atherosclerosis: The Role of PTX3. <i>Current Pharmaceutical Design</i> , 2011, 17, 38-46.	0.9	47
125	Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and differentiation potency. <i>Cardiovascular Research</i> , 2009, 83, 707-716.	1.8	46
126	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , 2021, 9, 268-277.	1.9	46

#	ARTICLE	IF	CITATIONS
127	Role of brain natriuretic peptide in the diagnosis and management of heart failure: Current concepts. <i>Journal of Cardiac Failure</i> , 2002, 8, 288-299.	0.7	45
128	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1711-1723.	2.9	43
129	Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 1-6.	0.8	43
130	Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 29-38.	0.6	42
131	Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. <i>Cardiovascular Research</i> , 2014, 104, 37-48.	1.8	42
132	The cardiokine secreted <sc>F</sc>rizzled-related protein 3, a modulator of <sc>W</sc>nt signalling, in clinical and experimental heart failure. <i>Journal of Internal Medicine</i> , 2014, 275, 621-630.	2.7	42
133	Amino-Terminal Pro-B-Type Natriuretic Peptides and Prognosis in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 101, S56-S60.	0.7	41
134	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart OMics in AGing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	41
135	Hydroxytyrosol Attenuates Peripheral Neuropathy in Streptozotocin-Induced Diabetes in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2012, 60, 5859-5865.	2.4	39
136	Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. <i>Canadian Journal of Cardiology</i> , 1997, 13, 1166-74.	0.8	39
137	Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?. <i>Heart Failure Reviews</i> , 2008, 13, 415-423.	1.7	38
138	Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 28.	0.7	38
139	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 735-748.	0.6	37
140	Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial. <i>Trials</i> , 2020, 21, 401.	0.7	37
141	Fish Oil and Perioperative Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004584.	0.9	36
142	Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS. <i>Critical Care</i> , 2021, 25, 113.	2.5	36
143	Early kynurenine pathway activation following cardiac arrest in rats, pigs, and humans. <i>Resuscitation</i> , 2013, 84, 1604-1610.	1.3	35
144	Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>American Heart Journal</i> , 2013, 166, 935-940.e1.	1.2	35

#	ARTICLE	IF	CITATIONS
145	LUCAS Versus Manual Chest Compression During Ambulance Transport: A Hemodynamic Study in a Porcine Model of Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2019, 8, e011189.	1.6	35
146	Early Activation of the Kynurenine Pathway Predicts Early Death and Long-term Outcome in Patients Resuscitated From Out-of-Hospital Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	34
147	Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. <i>Diabetes Care</i> , 2020, 43, 843-851.	4.3	34
148	ω -3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1289-1295.	2.9	33
149	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	0.8	32
150	Elevated Plasma and Alveolar Levels of Soluble Receptor for Advanced Glycation Endproducts Are Associated with Severity of Lung Dysfunction in ARDS Patients. <i>Tohoku Journal of Experimental Medicine</i> , 2010, 222, 105-112.	0.5	31
151	Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. <i>Heart</i> , 2010, 96, 1909-1914.	1.2	31
152	The ω -3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trial rationale and design. <i>American Heart Journal</i> , 2011, 162, 56-63.e3.	1.2	31
153	Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or Shock. <i>Clinical Chemistry</i> , 2018, 64, 1361-1369.	1.5	31
154	Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 746-754.	2.9	30
155	Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico Heart Failure trial. <i>Nutrition Research</i> , 2016, 36, 989-994.	1.3	30
156	Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 256-264.	1.9	30
157	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza) Tj ETQq1 1 0.784314 rgBT /Overlo 205-215.	1.5	30
158	Low D-dimer levels in sepsis: Good or bad?. <i>Thrombosis Research</i> , 2019, 174, 13-15.	0.8	30
159	Comparative Efficacy of a DA ₂ Agonist and a β -Blocker in Reducing Adrenergic Drive and Cardiac Fibrosis in an Experimental Model of Left Ventricular Dysfunction After Coronary Artery Occlusion. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, 601-608.	0.8	30
160	Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. <i>Heart</i> , 2009, 95, 1920-1924.	1.2	29
161	The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk. <i>Journal of Internal Medicine</i> , 2015, 277, 318-330.	2.7	29
162	Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis. <i>EuroIntervention</i> , 2010, 6, 527-536.	1.4	29

#	ARTICLE	IF	CITATIONS
163	Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort. <i>JACC: CardioOncology</i> , 2022, 4, 98-109.	1.7	29
164	Myocardial Infarction: Animal Models. , 2004, 98, 217-226.		28
165	Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico "Atrial Fibrillation (GISSI-AF) trial. <i>American Heart Journal</i> , 2011, 162, 382-389.	1.2	28
166	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 415-423.	3.1	28
167	Combining multiple ECG features does not improve prediction of defibrillation outcome compared to single features in a large population of out-of-hospital cardiac arrests. <i>Critical Care</i> , 2015, 19, 425.	2.5	28
168	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	0.8	28
169	CHANGES IN DIASTOLIC FUNCTION AND COLLAGEN CONTENT IN NORMOTENSIVE AND HYPERTENSIVE RATS WITH LONG-TERM STREPTOZOTOCIN-INDUCED DIABETES. <i>Pharmacological Research</i> , 1998, 37, 233-240.	3.1	27
170	Systematic Review and Meta-Analysis: Renin-Angiotensin System Inhibitors in the Prevention of Atrial Fibrillation Recurrences. An Unfulfilled Hope. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 47-54.	1.3	27
171	Copeptin levels are associated with organ dysfunction and death in the intensive care unit after out-of-hospital cardiac arrest. <i>Critical Care</i> , 2015, 19, 132.	2.5	27
172	Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 476-484.	1.1	27
173	Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. <i>Journal of Clinical Medicine</i> , 2020, 9, 1418.	1.0	27
174	PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study. <i>Journal of Internal Medicine</i> , 2021, 289, 179-192.	2.7	27
175	Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine?: GISSI experience, 1984-1993. <i>European Heart Journal</i> , 1997, 18, 1447-1456.	1.0	26
176	Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. <i>European Heart Journal</i> , 2002, 23, 536-542.	1.0	26
177	Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in Heart Failure Trial (Val-HeFT). <i>Journal of the American Society of Echocardiography</i> , 2002, 15, 293-307.	1.2	26
178	StarC II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 64, 375-382.	0.7	26
179	Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI) "3 trial. <i>American Heart Journal</i> , 2008, 155, 388-394.	1.2	26
180	Regular Wine Consumption in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 428-437.	1.6	26

#	ARTICLE	IF	CITATIONS
181	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, 2-9.	0.7	26
182	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	2.9	26
183	Efficacy of acute administration of inhaled argon on traumatic brain injury in mice. <i>British Journal of Anaesthesia</i> , 2021, 126, 256-264.	1.5	26
184	WITHIN-PATIENT VARIABILITY OF HORMONE AND CYTOKINE CONCENTRATIONS IN HEART FAILURE. <i>Pharmacological Research</i> , 1998, 37, 213-217.	3.1	25
185	L-selectin and SDF-1 enhance the migration of mouse and human cardiac mesoangioblasts. <i>Cell Death and Differentiation</i> , 2012, 19, 345-355.	5.0	25
186	Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from the PREDICTOR™, a population based study in central Italy. <i>European Journal of Heart Failure</i> , 2013, 15, 1102-1112.	2.9	25
187	Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. <i>Journal of Cardiac Failure</i> , 2004, 10, 433-441.	0.7	24
188	Prothrombotic Gene Expression Profile in Vascular Smooth Muscle Cells of Human Saphenous Vein, but Not Internal Mammary Artery. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 705-710.	1.1	24
189	Plasma Phospholipid Omega-3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial. <i>Journal of the American Heart Association</i> , 2013, 2, e000397.	1.6	24
190	High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals. <i>Journal of Internal Medicine</i> , 2013, 273, 306-317.	2.7	24
191	Elevations of inflammatory markers PTX3 and sST2 after resuscitation from cardiac arrest are associated with multiple organ dysfunction syndrome and early death. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1847-57.	1.4	24
192	Heart omics™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014, 28, 349.	0.7	24
193	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: Data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy. <i>Heart Rhythm</i> , 2013, 10, 226-232.	0.3	23
194	Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial. <i>European Journal of Clinical Investigation</i> , 2015, 45, 170-178.	1.7	23
195	Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. <i>European Journal of Heart Failure</i> , 2016, 18, 840-848.	2.9	23
196	Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock. <i>Critical Care Medicine</i> , 2018, 46, e404-e410.	0.4	23
197	Duration of Untreated Cardiac Arrest and Clinical Relevance of Animal Experiments: The Relationship Between the No-Flow-Duration and the Severity of Post-Cardiac Arrest Syndrome in a Porcine Model. <i>Shock</i> , 2018, 49, 205-212.	1.0	23
198	Simple estimate of the true right to left shunt (Qs/Qt) at maintenance FIO2 by Sulphur Hexafluoride retention. <i>Intensive Care Medicine</i> , 1982, 8, 283-286.	3.9	22

#	ARTICLE	IF	CITATIONS
199	Effect of β -adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats. <i>Life Sciences</i> , 2007, 81, 951-959.	2.0	22
200	Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico "Atrial Fibrillation (GISSI-AF) trial. <i>American Heart Journal</i> , 2010, 159, 857-863.	1.2	22
201	Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. <i>Pharmacological Research</i> , 2013, 73, 35-43.	3.1	22
202	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. <i>Clinica Chimica Acta</i> , 2015, 443, 85-93.	0.5	22
203	Cardiopulmonary Resuscitation-associated Lung Edema (CRALE). A Translational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 447-457.	2.5	22
204	Inhibition of human platelet thromboxane generation by aspirin in the absence of measurable drug levels in peripheral blood. <i>Biochemical Pharmacology</i> , 1985, 34, 1839-1841.	2.0	21
205	Ventilation in the prone position. <i>Lancet, The</i> , 1997, 350, 815.	6.3	21
206	Incorporation and washout of n-3 polyunsaturated fatty acids after diet supplementation in clinical studies. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, S4-S10.	0.6	21
207	Histone Deacetylase Inhibition Enhances Self Renewal and Cardioprotection by Human Cord Blood-Derived CD34+ Cells. <i>PLoS ONE</i> , 2011, 6, e22158.	1.1	21
208	Effects of a DA $_{2\pm 2}$ Agonist and a β -Blocker in Combination with an ACE Inhibitor on Adrenergic Activity and Left Ventricular Remodeling in an Experimental Model of Left Ventricular Dysfunction After Coronary Artery Occlusion. <i>Journal of Cardiovascular Pharmacology</i> , 1999, 34, 321-326.	0.8	21
209	Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2022, 179, 102418.	1.0	21
210	Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: The AREA-in-CHF study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 783-791.	1.1	20
211	Procalcitonin and Presepsin as Prognostic Markers After Out-of-Hospital Cardiac Arrest. <i>Shock</i> , 2018, 50, 395-400.	1.0	20
212	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	1.5	20
213	NT-proBNP for Risk Prediction in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	1.9	20
214	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 755-764.	2.9	19
215	Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>PLoS ONE</i> , 2015, 10, e0133970.	1.1	19
216	Relationship between post-cardiac arrest myocardial oxidative stress and myocardial dysfunction in the rat. <i>Journal of Biomedical Science</i> , 2014, 21, 70.	2.6	18

#	ARTICLE	IF	CITATIONS
217	Persistence of Central Venous Oxygen Desaturation During Early Sepsis Is Associated With Higher Mortality. <i>Chest</i> , 2018, 154, 1291-1300.	0.4	18
218	CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 131-138.	1.3	17
219	Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study. <i>Journal of Hypertension</i> , 2011, 29, 1994-2003.	0.3	17
220	Telomere/telomerase system impairment in circulating angiogenic cells of geriatric patients with heart failure. <i>International Journal of Cardiology</i> , 2013, 164, 99-105.	0.8	17
221	Septic shock-3 vs 2: an analysis of the ALBIOS study. <i>Critical Care</i> , 2018, 22, 237.	2.5	17
222	The role of resistin and myeloperoxidase in severe sepsis and septic shock: Results from the ALBIOS trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13333.	1.7	17
223	Antiinflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. <i>European Journal of Pharmacology</i> , 1989, 159, 257-264.	1.7	16
224	Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice. <i>European Journal of Pharmacology</i> , 1996, 317, 369-376.	1.7	16
225	Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. <i>Journal of Diabetes and Its Complications</i> , 1997, 11, 131-136.	1.2	16
226	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Cardiovascular Medicine</i> , 2007, 8, 683-691.	0.6	16
227	Anaesthesiological strategies in elective craniotomy: randomized, equivalence, open trial â€“ The NeuroMorfeo trial. <i>Trials</i> , 2009, 10, 19.	0.7	16
228	Pentraxin-3 Predicts Functional Recovery and 1-Year Major Adverse Cardiovascular Events After Rehabilitation of Cardiac Surgery Patients. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2012, 32, 17-24.	1.2	16
229	CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSIâ€™HF trials. <i>European Journal of Heart Failure</i> , 2013, 15, 747-755.	2.9	16
230	Unilateral Acid Aspiration Augments the Effects of Ventilator Lung Injury in the Contralateral Lung. <i>Anesthesiology</i> , 2013, 119, 642-651.	1.3	16
231	Circulating biomarkers and cardiac function over 3Âˆyears after chemotherapy with anthracyclines: the ICOSâ€™ONE trial. <i>ESC Heart Failure</i> , 2020, 7, 1452-1466.	1.4	16
232	Association of high-risk coronary atherosclerosis at CCTA with clinical and circulating biomarkers: Insight from CAPIRE study. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 73-80.	0.7	16
233	Sex differences in factors associated with heart failure and diastolic left ventricular dysfunction: a cross-sectional population-based study. <i>BMC Public Health</i> , 2021, 21, 415.	1.2	16
234	D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis. <i>Blood Transfusion</i> , 2020, 18, 304-311.	0.3	16

#	ARTICLE	IF	CITATIONS
235	In vivo cardioprotection by N-acetylcysteine and isosorbide 5-mononitrate in a rat model of ischemia-reperfusion. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 199-208.	1.3	15
236	An Update on Cardiac Troponins as Circulating Biomarkers in Heart Failure. <i>Current Heart Failure Reports</i> , 2010, 7, 15-21.	1.3	15
237	Elevated plasma heparin-binding protein is associated with early death after resuscitation from cardiac arrest. <i>Critical Care</i> , 2016, 20, 251.	2.5	15
238	A novel echocardiographic method closely agrees with cardiac magnetic resonance in the assessment of left ventricular function in infarcted mice. <i>Scientific Reports</i> , 2019, 9, 3580.	1.6	15
239	Ventilation With Argon Improves Survival With Good Neurological Recovery After Prolonged Untreated Cardiac Arrest in Pigs. <i>Journal of the American Heart Association</i> , 2020, 9, e016494.	1.6	15
240	Early osteopontin levels predict mortality in patients with septic shock. <i>European Journal of Internal Medicine</i> , 2020, 78, 113-120.	1.0	15
241	Circulating levels and prognostic cutoffs of sST2, hsTnT, and NT-proBNP in women vs. men with chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2084-2095.	1.4	15
242	Left ventricular response to beta-adrenergic stimulation in aging rats. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2000, 55, B35-B41.	1.7	14
243	Adiponectin in chronic heart failure: influence of diabetes and genetic variants. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1330-1338.	1.7	14
244	Left Atrial Remodeling and Response to Valsartan in the Prevention of Recurrent Atrial Fibrillation. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 721-728.	1.3	14
245	Coronary atherosclerosis in outlier subjects at the opposite extremes of traditional risk factors: Rationale and preliminary results of the Coronary Atherosclerosis in outlier subjects: Protective and novel Individual Risk factors Evaluation (CAPIRE) study. <i>American Heart Journal</i> , 2016, 173, 18-26.	1.2	14
246	Usefulness of High-Sensitivity Cardiac Troponin T for the Identification of Outlier Patients With Diffuse Coronary Atherosclerosis and Low-Risk Factors. <i>American Journal of Cardiology</i> , 2016, 117, 1397-1404.	0.7	14
247	Effect of mild hypercapnia on outcome and histological injury in a porcine post cardiac arrest model. <i>Resuscitation</i> , 2019, 135, 110-117.	1.3	14
248	A combination of untargeted and targeted metabolomics approaches unveils changes in the kynurenine pathway following cardiopulmonary resuscitation. <i>Metabolomics</i> , 2013, 9, 839-852.	1.4	13
249	ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure. <i>European Heart Journal Supplements</i> , 2017, 19, D102-D112.	0.0	13
250	High- and low-affinity PEGylated hemoglobin-based oxygen carriers: Differential oxidative stress in a Guinea pig transfusion model. <i>Free Radical Biology and Medicine</i> , 2018, 124, 299-310.	1.3	13
251	Adjuvant Radiochemotherapy in High-Risk Rectal Cancer Results of a Prospective Non-Randomized Study. <i>Tumori</i> , 2001, 87, 239-247.	0.6	12
252	Signs and symptoms in chronic heart failure: Relevance of clinical trial results to point of care-data from Val-HeFT. <i>European Journal of Heart Failure</i> , 2006, 8, 502-508.	2.9	12

#	ARTICLE	IF	CITATIONS
253	Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertension. <i>European Journal of Pharmacology</i> , 2011, 667, 287-291.	1.7	12
254	A low plasma 1,25(OH) ₂ vitamin D/PTH (1â€“84) ratio predicts worsening of renal function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 220-225.	0.8	12
255	Interaction of Galectin-3 Concentrations with the Treatment Effects of Î²-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF. <i>Clinical Chemistry</i> , 2016, 62, 605-616.	1.5	12
256	Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSIâ€“HF trial. <i>ESC Heart Failure</i> , 2020, 7, 3288-3297.	1.4	12
257	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 553.	0.7	12
258	Increased erythropoietin production after myocardial infarction in mice. <i>Heart</i> , 2005, 92, 838-839.	1.2	11
259	What is the atrium trying to tell us?. <i>European Heart Journal</i> , 2013, 34, 255-257.	1.0	11
260	Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 551-561.	1.3	11
261	Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor. <i>European Journal of Pharmacology</i> , 2019, 865, 172777.	1.7	11
262	Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 131-143.	1.3	10
263	Myocardial Infarction: Cardioprotection by Erythropoietin. <i>Methods in Molecular Biology</i> , 2013, 982, 265-302.	0.4	10
264	Novel biomarkers and therapies in cardiorenal syndrome. <i>Current Opinion in Pharmacology</i> , 2016, 27, 56-61.	1.7	10
265	Clinical and prognostic value of spot urinary creatinine in chronic heart failureâ€“An analysis from GISSI-HF. <i>American Heart Journal</i> , 2017, 188, 189-195.	1.2	10
266	Coronary sinus perforation during reducer implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1291-1293.	0.7	10
267	Predictive value of interatrial block for atrial fibrillation in elderly subjects enrolled in the PREDICTOR study. <i>Journal of Electrocardiology</i> , 2019, 54, 22-27.	0.4	10
268	Circulating pentraxin 3 in severe COVIDâ€“19 or other pulmonary sepsis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13530.	1.7	10
269	Aspirin use is associated with increased risk for incident heart failure: a patientâ€“level pooled analysis. <i>ESC Heart Failure</i> , 2022, 9, 685-694.	1.4	10
270	The Angiotensin-receptor Blockers: From Antihypertensives to Cardiovascular All-round Medications in 10 Years?. <i>Blood Pressure</i> , 2002, 11, 328-338.	0.7	9

#	ARTICLE	IF	CITATIONS
271	Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest. <i>Heart Rhythm</i> , 2014, 11, 1641-1647.	0.3	9
272	Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes. <i>Life Sciences</i> , 2016, 154, 87-95.	2.0	9
273	LIPCAR Is Increased in Chronic Symptomatic HF Patients. A Sub-Study of the GISSI-HF Trial. <i>Clinical Chemistry</i> , 2021, 67, 1721-1731.	1.5	9
274	IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 328.	0.7	9
275	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 Å– 2 phenotypic CAPIRE study. <i>International Journal of Cardiology</i> , 2021, 336, 14-21.	0.8	9
276	Reperfusion in STEMI patients: still a role for cardioprotection?. <i>Minerva Cardiology and Angiology</i> , 2018, 66, 452-463.	0.4	9
277	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. <i>Annals of Medicine</i> , 2022, 54, 1036-1046.	1.5	9
278	Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI) Tj ETQq0 0 0 rgBT./Overlogk 10 Tf 50	0.7	9
279	Analytical Agreement and Clinical Correlates of Plasma Brain Natriuretic Peptide Measured by Three Immunoassays in Patients with Heart Failure. <i>Clinical Chemistry</i> , 1997, 43, 2439-2440.	1.5	8
280	How to use ACE-inhibitors, ð²-blockers, and newer therapies in AMI. <i>American Heart Journal</i> , 1999, 138, S183-S187.	1.2	8
281	Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the delapril remodeling after acute myocardial infarction (DRAM1) trial. <i>American Heart Journal</i> , 2003, 146, 133A-140A.	1.2	8
282	Levels of Circulating Pro-angiogenic Cells Predict Cardiovascular Outcomes in Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 747-755.	0.7	8
283	Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: in vitro and in vivo studies. <i>Cytotherapy</i> , 2011, 13, 1140-1152.	0.3	8
284	A mouse model for spatial and temporal expression of HGF in the heart. <i>Transgenic Research</i> , 2011, 20, 1203-1216.	1.3	8
285	Cancer in chronic heart failure patients in the GISSIâ€HF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13273.	1.7	8
286	Magic TouchÂ®: preliminary clinical evidence with a novel sirolimus drug coated balloon. <i>Minerva Cardiology and Angiology</i> , 2018, 66, 508-517.	0.4	8
287	Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 790289.	1.1	8
288	Safety of ventilation with an argon and oxygen gas mixture. <i>British Journal of Anaesthesia</i> , 2019, 122, e31-e32.	1.5	7

#	ARTICLE	IF	CITATIONS
289	Modes of death and prognostic outliers in chronic heart failure. <i>American Heart Journal</i> , 2019, 208, 100-109.	1.2	7
290	Prognostic Value of a Combination of Circulating Biomarkers in Critically Ill Patients with Traumatic Brain Injury: Results from the European CReACTIVE Study. <i>Journal of Neurotrauma</i> , 2021, 38, 2667-2676.	1.7	7
291	Effects of a New Angiotensin-Converting Enzyme Inhibitor (Idrapril) in Rats with Left Ventricular Dysfunction After Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 347-354.	0.8	7
292	Cardiac dysfunction and circulating cardiac markers during sepsis. <i>Minerva Anestesiologica</i> , 2016, 82, 697-710.	0.6	7
293	What does the future hold for BNP in cardiology?. <i>British Heart Journal</i> , 2001, 86, 601-602.	2.2	6
294	Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling. <i>Current Heart Failure Reports</i> , 2006, 3, 157-163.	1.3	6
295	Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 315-321.	1.3	6
296	Significance of measurable cardiac troponin by high-sensitivity assays in patients with chronic stable heart failure. <i>Coronary Artery Disease</i> , 2013, 24, 716-719.	0.3	6
297	The Effects of Exogenous Surfactant Treatment in a Murine Model of Two-Hit Lung Injury. <i>Anesthesia and Analgesia</i> , 2015, 120, 381-388.	1.1	6
298	Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 703-711.	0.6	6
299	Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more. <i>European Journal of Heart Failure</i> , 2020, 22, 300-302.	2.9	6
300	Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008382.	2.1	6
301	Semaglutide and effective weight control. <i>Lancet, The</i> , 2021, 397, 942-943.	6.3	6
302	Esmolol during cardiopulmonary resuscitation reduces neurological injury in a porcine model of cardiac arrest. <i>Scientific Reports</i> , 2021, 11, 10635.	1.6	6
303	Higher levels of IgA and IgG at sepsis onset are associated with higher mortality: results from the Albumin Italian Outcome Sepsis (ALBIOS) trial. <i>Annals of Intensive Care</i> , 2021, 11, 161.	2.2	6
304	Screening for unknown atrial fibrillation in older people: a feasibility study in community pharmacies. <i>European Geriatric Medicine</i> , 2018, 9, 113-115.	1.2	5
305	Pentraxin-3, Troponin T, N-Terminal Pro-B-Type Natriuretic Peptide in Septic Patients. <i>Shock</i> , 2020, 54, 675-680.	1.0	5
306	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. <i>Cancers</i> , 2020, 12, 2312.	1.7	5

#	ARTICLE	IF	CITATIONS
307	Testing longitudinal data for prognostication in ambulatory heart failure patients with reduced ejection fraction. A proof of principle from the GISSI-HF database. <i>International Journal of Cardiology</i> , 2020, 313, 89-96.	0.8	5
308	Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 11236-11245.	2.4	5
309	NT-proBNP: A Guide to Improve the Management of Patients with Heart Failure. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2013, 24, 78-84.	0.7	5
310	Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study. <i>Metabolites</i> , 2022, 12, 123.	1.3	5
311	Recommendations for the clinical use of cardiac natriuretic peptides. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2005, 6, 430-46.	0.1	5
312	Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study. <i>Cells</i> , 2022, 11, 669.	1.8	5
313	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. <i>European Journal of Heart Failure</i> , 2022, 24, 976-984.	2.9	5
314	Myocardial Infarction: When and How Should We Initiate Treatment with ACE Inhibitors?. <i>Cardiology</i> , 1996, 87, 16-22.	0.6	4
315	Valsartan for the treatment of heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 181-193.	0.9	4
316	The effect of a single bolus of exogenous surfactant on lung compliance persists until two weeks after treatment in a model of acid aspiration pneumonitis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 141-146.	1.1	4
317	The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2014, 176, 1249-1251.	0.8	4
318	Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 8-17.	0.8	4
319	Albumin Oxidation Status in Sepsis Patients Treated With Albumin or Crystalloids. <i>Frontiers in Physiology</i> , 2021, 12, 682877.	1.3	4
320	Demonstration of a different sensitivity to epinephrine in isolated and in vivo hearts. <i>European Journal of Pharmacology</i> , 1988, 156, 87-94.	1.7	3
321	Cardiac protection by pharmacological modulation of inflammation. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1913-1924.	1.9	3
322	Cardiac Fibrosis and Aging. , 2005, , 97-103.		3
323	Cardiovascular Biomarkers, Cardiac Dysfunction, and Outcomes in Patients With Type 2 Diabetes: A Prospective, Multicenter Study. <i>Diabetes Care</i> , 2013, 36, e137-e138.	4.3	3
324	Natriuretic peptides in acute chest pain and acute coronary syndrome. <i>Coronary Artery Disease</i> , 2013, 24, 33-39.	0.3	3

#	ARTICLE	IF	CITATIONS
325	Understanding and making good use of changes in natriuretic peptide levels in chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 758-759.	2.9	3
326	Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. <i>Diabetes Research and Clinical Practice</i> , 2018, 146, 172-179.	1.1	3
327	Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2a, ¢ Trial). Rationale, Design, and Baseline Characteristics of the Study Population. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 547-555.	1.3	3
328	Treatment of acute myocardial infarction today. <i>American Heart Journal</i> , 1997, 134, s9-s14.	1.2	2
329	RAAS Inhibitors in the Cardiovascular Continuum: What is Still Missing?. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 311-320.	1.3	2
330	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , 2008, 30, 223-230.	0.6	2
331	Biomarkers of Myocyte Injury in Heart Failure. <i>Heart Failure Clinics</i> , 2009, 5, 529-536.	1.0	2
332	An opto-structural method to estimate the stress-strain field induced by cell contraction on substrates of controlled stiffness in vitro. <i>Journal of Applied Biomaterials and Functional Materials</i> , 2013, 11, 143-150.	0.7	2
333	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials." <i>Circulation</i> , 2015, 132, e358.	1.6	2
334	Adrenomedullin, a circulating biomarker of congestion: in search of evidence. <i>European Journal of Heart Failure</i> , 2019, 21, 1062-1063.	2.9	2
335	Searching for Preclinical Models of Acute Decompensated Heart Failure: a Concise Narrative Overview and a Novel Swine Model. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 727-738.	1.3	2
336	Brain Kynurenine Pathway and Functional Outcome of Rats Resuscitated From Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2021, 10, e021071.	1.6	2
337	Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002708.	1.2	2
338	Corrigendum to "Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial" [Eur J Heart Fail 2010;12:1345-1353]. <i>European Journal of Heart Failure</i> , 2011, 13, 1042-1042.	2.9	1
339	Reduction In body weight is an independent risk factor for mortality in chronic heart failure. Insights from GISSI-HF and Val-HeFT trials. <i>European Heart Journal</i> , 2013, 34, P1526-P1526.	1.0	1
340	1050. <i>Critical Care Medicine</i> , 2013, 41, A264.	0.4	1
341	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , 2014, 35, 351-357.	0.6	1
342	Characterization of anp genetic variant rs5068 in chronic heart failure patients. <i>Atherosclerosis</i> , 2014, 235, e223.	0.4	1

#	ARTICLE	IF	CITATIONS
343	HOME HF: an honest report of an (apparently) doable study. <i>European Journal of Heart Failure</i> , 2018, 20, 481-482.	2.9	1
344	Risk stratification according to insulin type: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1498-1498.	2.9	1
345	Primary pulmonary arterial hypertension: Protocol to assess comprehensively in the rat the response to pharmacologic treatments. <i>MethodsX</i> , 2020, 7, 100771.	0.7	1
346	Cardiovascular mortality and morbidity burden in successive and age pre-stratified caseâ€“control cohorts of breast cancer women. A population-based study. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 177-188.	1.1	1
347	Albumin replacement therapy in immunocompromised patients with sepsis â€“ Secondary analysis of the ALBIOS trial. <i>Journal of Critical Care</i> , 2021, 63, 83-91.	1.0	1
348	Ventilation with the noble gas argon in an in vivo model of idiopathic pulmonary arterial hypertension in rats. <i>Medical Gas Research</i> , 2021, 11, 124.	1.2	1
349	Idrapril, A Novel ACE Inhibitor. <i>Cardiovascular Drug Reviews</i> , 1996, 14, 351-363.	4.4	0
350	Use of ACE-inhibitors lowered the rate of mortality, reinfarction, and hospital readmission in patients with heart failure or left ventricular dysfunction. <i>Evidence-based Cardiovascular Medicine</i> , 2000, 4, 74.	0.0	0
351	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , 2004, , 203-208.	0.6	0
352	The long pentraxin PTX3: from innate immunity to ischemic heart disorders. <i>International Congress Series</i> , 2004, 1262, 63-66.	0.2	0
353	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , 2005, , 217-222.	0.6	0
354	18 Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , 2007, , 194-201.	0.6	0
355	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , 2009, 31, 339-343.	0.6	0
356	Plasma And Alveolar Fluid Levels Of Receptor For Advanced Glycation Endproducts (RAGE) Are Associated With Severity Of ARDS. , 2010, , .		0
357	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , 2010, , 363-369.	0.6	0
358	Beta-adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , 2011, 33, 397-406.	0.6	0
359	Role of reninâ€“angiotensin system inhibitors in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 374.	0.6	0
360	Prevention of Myocardial Remodeling by Chronic INaL Blockade in Pulmonary Hypertension. <i>Biophysical Journal</i> , 2012, 102, 340a.	0.2	0

#	ARTICLE	IF	CITATIONS
361	Beta-adrenoceptor antagonists and antianginal drugs. Side Effects of Drugs Annual, 2012, 34, 303-310.	0.6	0
362	The ANP Genetic Variant rs5068 Is Associated with Higher Circulating Concentrations of Natriuretic Peptides in Patients with Chronic Heart Failure. Journal of Cardiac Failure, 2013, 19, S30.	0.7	0
363	Î²-Adrenoceptor Antagonists and Antianginal Drugs. Side Effects of Drugs Annual, 2014, , 267-273.	0.6	0
364	Beta-Adrenoceptor Antagonists and Antianginal Drugs. Side Effects of Drugs Annual, 2015, 37, 215-222.	0.6	0
365	[OP.1B.10] RISK SCORE FOR INCIDENT HEART FAILURE. Journal of Hypertension, 2016, 34, e7.	0.3	0
366	Research update for articles published in EJCI in 2015. European Journal of Clinical Investigation, 2017, 47, 775-788.	1.7	0
367	Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure. Circulation Journal, 2017, 81, 1543-1546.	0.7	0
368	The authors reply. Critical Care Medicine, 2018, 46, e959-e961.	0.4	0
369	PMCA4 inhibition does not affect cardiac remodelling following myocardial infarction, but may reduce susceptibility to arrhythmia. Scientific Reports, 2021, 11, 1518.	1.6	0
370	In Search of the Lost Ark. JACC: Heart Failure, 2021, 9, 636-637.	1.9	0
371	The Heart in Diabetes: Results of Trials. , 2000, , 55-65.		0
372	287 Metabolic syndrome in chronic heart failure: prevalence and relation to clinical features and aetiology. European Journal of Heart Failure, Supplement, 2007, 6, 61-61.	0.2	0
373	668 Prevalence and significance of microalbuminuria in a large population of patients with chronic heart failure: data from the Italian GISSI-HF trial. European Journal of Heart Failure, Supplement, 2007, 6, 145-145.	0.2	0
374	Pentraxins and Atherosclerosis. , 2012, , 219-237.		0
375	Circulating Cardiac Biomarkers and Outcome. , 2014, , 211-217.		0
376	The Heart in Diabetes: Results of Trials. , 1998, , 51-60.		0
377	Pentraxins in Vascular Pathology: The Role of PTX3. , 0, , 137-154.		0